Navigation Links
Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
Date:4/24/2012

ting activities for the first quarter of 2012 was $144 million compared to $151 million for the first quarter of 2011.  Higher use of cash for working capital to support higher sales levels was the primary contributor to the decline in operating cash flow.  Capital expenditures were $32 million in the first quarter of 2012 compared to $18 million in the first quarter of 2011.  Free cash flow of $112 million for the first quarter of 2012, $193 million of short-term debt and the partial use of cash on hand were used to fund $389 million of acquisitions, pay $24 million in dividends and return $25 million to shareholders through share repurchases.  The Company's debt to capital ratio was 24% at March 31, 2012 and 19% at December 31, 2011. 

Share Repurchases: We acquired 0.4 million shares in the first quarter of 2012 at an average share price of $71.86. There were 121 million shares outstanding at March 31, 2012. The Company expects to continue to offset the dilutive impact of issuing share based incentive compensation with future repurchases,  the timing and amount of which will depend upon market conditions and other factors.

Cautionary Statement: This release contains forward-looking statements.  Such statements involve risk and uncertainty, including financial, business environment and projections, and relate to matters that are not historical facts.  Such statements are preceded by, followed by or include the words "believes," "can," "expects," "plans," "anticipates," "should," "enhances," "estimates," "forecasts," "will" or similar expressions.  Additionally, this release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs, including, without limitation, statements with respect to the Company's expectations, goals, beliefs, intentions, outlook, plans and the like regarding future
'/>"/>

SOURCE Sigma-Aldrich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. CRF Institute Names Sigma-Aldrich Top Employer Europe 2012
2. Sigma-Aldrich Enhances Asia-Pacific Customer Support With New Distribution and Packaging Capabilities in India
3. Sigma-Aldrich Corporation Will Hold Its Business Review March 29, 2012
4. Sigma-Aldrich (Nasdaq:SIAL) Declares Increased Quarterly Dividend
5. Sigma-Aldrich Completes Acquisition of BioReliance
6. Avista Capital Partners Agrees to Sell BioReliance to Sigma-Aldrich Corporation
7. Sigma-Aldrich Corporation to Present at Upcoming Investor Conference
8. Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81.
9. Sigma-Aldrich Corporation to Present at Upcoming Investor Conferences
10. Sigma-Aldrich (NASDAQ:SIAL) Declares Quarterly Dividend
11. Sigma-Aldrich Opens European Headquarters in St. Gallen, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... LAGUNA HILLS, Calif. , July 30, 2015 ... developing nanoparticle drug delivery platforms, has received Orphan ... (FDA) for a second drug product that uses ... is a formulation of dactinomycin for the treatment ... bone cancer. The FDA granted NanoSmart,s Orphan Drug ...
(Date:7/30/2015)... , July 30, 2015  Arena Pharmaceuticals, Inc. (NASDAQ: ... conference call and webcast at 5:00 p.m. Eastern Time ... to discuss second quarter 2015 financial results and provide ... after the NASDAQ Global Select Market closes that day. ... dialing 877.643.7155 for domestic callers and 914.495.8552 for international ...
(Date:7/30/2015)... , July 30, 2015 EnteroMedics Inc. ... using neuroblocking technology to treat obesity, metabolic diseases and ... a conference call on Thursday, August 6, 2015, at ... the second quarter ended June 30, 2015, and to ... vBloc® Neurometabolic Therapy, delivered via the Maestro® System. ...
Breaking Medicine Technology:NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 3
... July 28 Accuray Incorporated (Nasdaq: ARAY ), a global leader in ... quarter and fiscal year 2010, ended June 30, 2010 on Tuesday, ... , , ... / 5:00 p.m. ET and will be hosted by Euan S. Thomson ...
... , July 28 HemaQuest Pharmaceuticals, a ... sickle cell disease, beta thalassemia and EBV-related cancers, announced ... to its Series B financing by new investor, Latterell ... financing to $16M . The financing is intended ...
Cached Medicine Technology:Accuray Incorporated to Report Financial Results for Fourth Quarter and Fiscal Year 2010 2Accuray Incorporated to Report Financial Results for Fourth Quarter and Fiscal Year 2010 3Accuray Incorporated to Report Financial Results for Fourth Quarter and Fiscal Year 2010 4HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing 2
(Date:7/31/2015)... ... July 31, 2015 , ... David Gilpin, ... website to inform potential Nashville area sinus sufferers about the benefits ... to determine if someone is a good candidate for Balloon Sinuplasty. The questionnaire ...
(Date:7/30/2015)... Tucson, AZ (PRWEB) , ... July 31, 2015 , ... ... getaways may seem impossible or out-of-reach. The questions race through your mind: What happens ... is a storm? You feel overwhelmed and cancel your plans. , But not taking ...
(Date:7/30/2015)... ... July 31, 2015 , ... Reduce Human ... More, **Presented by FDAnews and Ginette M. Collazo, Inc.**, Sept. 16-17, 2015 – ... of helping drug, biologic and device firms reduce manufacturing errors by 50 percent ...
(Date:7/30/2015)... ... July 31, 2015 , ... On July 22nd the ... Manatee county to discuss plausible solutions for controlling the heroin outbreak. Ultimately the committee ... an overdose is largely perpetuating the heroin crisis in North Florida. The task force ...
(Date:7/30/2015)... ... July 30, 2015 , ... World Patent Marketing, a vertically ... invention that can help people during emergencies. , "The worldwide mobile health market ... Director of World Patent Marketing. "Currently, there are about 97,000 mobile health apps ...
Breaking Medicine News(10 mins):Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 2Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 3Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 2Health News:Manatee County’s Opioid Task Force Calls for More Funding and Face to Face Counseling After Overdose 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 2Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 3Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 4Health News:Emergency Alert Can Be A Rude Awakening Without World Patent Marketings New App Invention, I AM FINE 5
... Barcelona, Spain: An experimental drug that attacks cancer in ... advanced melanoma, delaying progression of the disease and prolonging ... (Wednesday) at the European Cancer Conference (ECCO 14) in ... to chemotherapy more than doubled the amount of time ...
... 26 Biomedtex Inc.,(Pink Sheets: PDNL.PK) ("Biomed" or ... that A. Marc Rocca, 42, will be,President and ... mission is to identify, evaluate and assess a ... and then,seek to capture and promote innovations with ...
... Nycomed Acquires Exclusive Rights Outside North America in Deal Valued ... ... N.J. and ZURICH, Switzerland, Sept. 26, NPS Pharmaceuticals, Inc. (Nasdaq: ... into a definitive agreement,which licenses to Nycomed the rights to ...
... research has yielded a clearer picture of which biomarkers ... colon cancer, bringing closer the day when patients who ... those that will, get the more aggressive treatment they ... doctors plan treatment of colon cancer chiefly by staging ...
... work investigating the reproducibility of glycemic index values, ... Research Center on Aging at Tufts University (USDA ... determinations (measure of the rate of glucose absorption ... white bread, resulted in a relatively high level ...
... to Home and the ... ... pioneer and largest provider of retail-,based health care in the United ... stores in Southeastern,Pennsylvania and Southern New Jersey. MinuteClinic plans to open ...
Cached Medicine News:Health News:New type of drug shows promise in attacking melanoma in an innovative way 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 2Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 3Health News:NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America 4Health News:Study makes progress in zoning in on biomarkers for better colon cancer treatment 2Health News:Glycemic index values are variable, report researchers 2Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Philadelphia Metro Area 2Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Philadelphia Metro Area 3Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Philadelphia Metro Area 4Health News:An Innovation in Health Care Opens at CVS/pharmacy Stores in Philadelphia Metro Area 5
Includes one aluminum pediatric eye shield and one eye garter shield cover. Packaged 50 per box. White only....
Non-linting, quick absorption and rounded corners. Tapered malleable handle. Dispenser carton contains 25 envelopes, each envelope contains 10 sponges packaged sterile in Tyvek peel-back pouch....
Straight, right side cutting, 1.5 mm x 4 mm bite, length of shaft 115 mm, overall length 6.3 inches....
Large: 22 x 25 mm, 0.9 x 1.0 inches. With holes. For support of the orbital rim following enucleation. Available in methylmethacrylate....
Medicine Products: